Emergent BioSolutions (EBS) Accumulated Depreciation & Amortization: 2010-2025
Historic Accumulated Depreciation & Amortization for Emergent BioSolutions (EBS) over the last 10 years, with Sep 2025 value amounting to $23.4 million.
- Emergent BioSolutions' Accumulated Depreciation & Amortization fell 11.36% to $23.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $98.3 million, marking a year-over-year decrease of 12.54%. This contributed to the annual value of $108.8 million for FY2024, which is 13.03% down from last year.
- According to the latest figures from Q3 2025, Emergent BioSolutions' Accumulated Depreciation & Amortization is $23.4 million, which was down 0.43% from $23.5 million recorded in Q2 2025.
- Emergent BioSolutions' 5-year Accumulated Depreciation & Amortization high stood at $44.5 million for Q2 2022, and its period low was $23.4 million during Q3 2025.
- Moreover, its 3-year median value for Accumulated Depreciation & Amortization was $27.9 million (2024), whereas its average is $27.8 million.
- As far as peak fluctuations go, Emergent BioSolutions' Accumulated Depreciation & Amortization surged by 182.25% in 2021, and later fell by 26.07% in 2023.
- Over the past 5 years, Emergent BioSolutions' Accumulated Depreciation & Amortization (Quarterly) stood at $29.2 million in 2021, then grew by 22.26% to $35.7 million in 2022, then dropped by 17.09% to $29.6 million in 2023, then dropped by 12.16% to $26.0 million in 2024, then declined by 11.36% to $23.4 million in 2025.
- Its Accumulated Depreciation & Amortization was $23.4 million in Q3 2025, compared to $23.5 million in Q2 2025 and $25.4 million in Q1 2025.